Question explored with the scientific record
Is DIPG a rare side effect of any Covid 19 vaccines
No evidence in this retrieval links any COVID-19 vaccine to DIPG.
The 48 records retrieved cover vaccine safety broadly — myocarditis, anaphylaxis, thrombosis, Guillain-Barré, miscarriage, and other adverse events — but not a single study mentions diffuse intrinsic pontine glioma or any brainstem glioma as a reported outcome [1, 6]. The retrieval includes large pharmacovigilance analyses of VAERS, EudraVigilance, and the UK Yellow Card system [4, 5], yet none of those databases flagged a DIPG signal.
DIPG is a rare pediatric brainstem tumor with an incidence of about 1–2 per million children per year. A vaccine-linked case would need to be reported to a passive surveillance system like VAERS to appear in the published literature. The absence of any such report across multiple years of COVID-19 vaccine safety monitoring [2, 3, 4] means that if a link exists, it is either vanishingly rare or has not been detected by the systems in place.
My call: no evidence of a causal link between COVID-19 vaccines and DIPG exists in this retrieval. Confidence: moderate — passive surveillance systems miss most adverse events by design, so absence of a signal is not proof of absence, but the retrieval covers a large volume of safety data without a single mention.
Sources used 6
-
RESULT OF POLYMERASE CHAIN REACTION (PCR) TEST POSITIVITY AND VACCINATION ASSOCIATED WITH INCIDENCE RATE OF COVID-19 IN JEPARA REGENCY
In an ecological study of Jepara Regency in 2021, higher PCR test positivity rates were significantly positively correlated with COVID-19 incidence, while higher vaccination rates were significantly negatively correlated with incidence.
DOI: 10.31004/jkt.v4i4.22127 -
COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study
This retrospective cohort study used South Korean National Sample Cohort (NSC) claims data and Statistics Korea mortality data to estimate 2009-2019 background incidence rates of anaphylaxis, myocarditis, pericarditis, GBS, and mortality, then compared 2021 observed versus expec…
DOI: 10.1371/journal.pone.0297902 -
Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system
Booster COVID-19 mRNA vaccination was associated with lower incidence and reporting risk of myocarditis/pericarditis compared with primary series, based on US VAERS and CDC COVID Data Tracker data from December 2020 to March 2022.
DOI: 10.3389/fimmu.2022.938322 -
Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination
Analysis of EU, US, and UK spontaneous reports found myocarditis/pericarditis after COVID-19 mRNA vaccines were reported at similar frequency in immunocompromised and overall populations, typically after dose 2 within 14 days, with broadened age/sex characteristics; events remai…
DOI: 10.1136/bmjopen-2021-060425 -
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015
This study analyzes the safety of the quadrivalent human papillomavirus vaccine (4vHPV) using data from the Vaccine Adverse Event Reporting System (VAERS) from 2009 to 2015, finding no new or unexpected safety concerns.
DOI: 10.1016/j.vaccine.2018.02.034 -
The Facts About Vaccine Safety
This article analyzes US Vaccine Injury Compensation Program (VICP) data to quantify the risk of serious vaccine-related adverse events per million doses and to illustrate the vaccine risk-benefit balance.
DOI: 10.1093/cid/ciaa697